Genotyping and outcomes of presumptive second line ART failure cases switched to third line or maintained on second line ART in Mumbai, India

English version

Autoři: Naresh Gill ^aff001; Rafael Van den Bergh ^aff002; Khine Wut Yee Kyaw ^aff003; Chinmay Laxmeshwar ^aff001; Mrinalini Das ^aff001; Sarthak Rastogi ^aff001; Miriam Arago Galindo ^aff001; Homa Mansoor ^aff001; Stobdan Kalon ^aff001; Petros Isaakidis ^aff004
Působiště autorů: Médecins Sans Frontières, Mumbai, India ^aff001; Médecins Sans Frontières, Brussels, Belgium ^aff002; International Union Against Tuberculosis and Lung diseases, Mandalay, Myanmar ^aff003; Southern Africa Medical Unit (SAMU), Médecins Sans Frontières, Cape Town, South Africa ^aff004
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0225631

Souhrn

Background

HIV programs are increasingly confronted with failing antiretroviral therapy (ART), including second-line regimens. WHO has provided guidelines on switching to third-line ART. In a Médecins Sans Frontières clinic in Mumbai, India, receiving referred presumptive second-line ART failure cases, an evidence-based protocol consisting of viral load (VL) testing, enhanced adherence counselling (EAC) and genotype for switching was implemented.

Objective

To document the outcome and genotype of presumptive second-line ART failure cases switched to third-line or maintained on second-line ART.

Design

Retrospective cohort study of patients referred between January 2011 and September 2017.

Results

The cases (n = 120) were complex with median 9.2 years of ART exposure, poor adherence at baseline, and exposure to multiple ART regimens other than recommended by WHO. Out of 90 evaluated cases, 39(43%) were maintained on second-line ART. Forty-nine (54%) were ever switched to third-line ART. Twelve months virological suppression was 72% in the second-line and 93% in the third-line ART cohort, while retention in care was 80% and 94% respectively. Genotyping showed 62% resistance for PIs, and 52% triple class resistance to NRTIs, NNRTIs and PIs. Resistance was noted for the new class of integrase inhibitors, and for different drugs without any documented previous exposure to the same drug.

Conclusion

Adopting WHO guidelines on switching ART regimens and provision of EAC can prevent unnecessary switching/exposure to third-line ART regimens. Genotyping is urgently required in national HIV programs, which currently use only the exposure history of patients for switching to third-line ART regimens.

Klíčová slova:

Viral load – India – Antimicrobial resistance – HIV epidemiology – Mutation detection – Genotyping

Zdroje

1. UNAIDS. Global HIV & AIDS statistics—2018 fact sheet | UNAIDS [Internet]. [cited 14 Dec 2018]. Available: http://www.unaids.org/en/resources/fact-sheet

2. United Nations. Sustainable Development Goals [Internet]. 2015.

3. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic [Internet]. 2014. Available: http://www.unaids.org/Sites/Default/Files/Media_Asset/90-90-90_En_0.Pdf

4. World Health Organization. Policy Brief: Consolidated guidelines on the use of Antiretroviral Drugs for treating and preventing HIV infection: What’s New. 2015. doi: 10.1017/CBO9781107415324.004

5. Isaakidis P, Gupta S, Das M, Ferrer D, Nalinikanta R, Reid T, et al. HIV viral load messages should go viral in India. Lancet HIV. Elsevier Ltd; 2015;2: e414–e415. doi: 10.1016/S2352-3018(15)00180-0 26423648

6. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges. Clin Infect Dis. 2016;62: 1043–1048. doi: 10.1093/cid/ciw001 26743094

7. World Health Organization. The Availability and use of HIV diagnostics: A 2012–2013 who survey in Low and middle income countries. 2014.

8. Kumarasamy N, Krishnan S. Beyond first-line HIV treatment regimens. Curr Opin HIV AIDS. 2013;8: 586–590. doi: 10.1097/COH.0000000000000004 24100872

9. Van Vaerenbergh K. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Verh K Acad Geneeskd Belg. 2001;63: 447–73. 11813503

10. National AIDS Control Organisation. National Strategic Plan for HIV/AIDS and STI,2017. New Delhi; 2017.

11. Department of Health & Family Welfare. NACO Annual Report 2016–17. New Delhi; 2017.

12. UNAIDS. South Africa | UNAIDS [Internet].

13. Ramchandani SR, Mehta SH, Saple DG, Vaidya SB, Pandey VP, Vadrevu R, et al. Knowledge, Attitudes, And Practices of Antiretroviral Therapy among HIV-Infected Adults Attending Private And Public Clinics in India. AIDS Patient Care STDS. 2007;21: 129–142. doi: 10.1089/apc.2006.0045 17328662

14. MINISTRY OF HEALTH AND FAMILY WELFARE. Report of the National Commission on Macroeconomics and Health. 2005.

15. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach [Internet]. 2013. 978 92 4 150572 7

16. Ministry of Health and Family Welfare. Guidelines for provision of third line ART inder National AIDS Control Programme. New Delhi; 2016. p. 2.

17. Mumbai District AIDS Control Society. Care & Support and Treatment (CST) [Internet].

18. Maharashtra State AIDS Control Society. ART [Internet].

19. National AIDS Control Organisation. Training modules for Medical Officers on HIV care and Treatment. New Delhi; 2007.

20. World Health Organization. HIV TREATMENT AND CARE. 2015.

21. World Health Organization. Antiretroviral therapy for HIV Infection in adults and adolescents. World Health Organization. Geneva; 2010.

22. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Heal Organ. 2016; 155 p.

23. World Health Organization. Consolidated Guidelines on HIV prevention, diagnosis, treatment and care for key populations-2016 update. 2016.

24. O’Brien DP, Venis S, Greig J, Shanks L, Ellman T, Sabapathy K, et al. Provision of antiretroviral treatment in conflict settings: the experience of Médecins Sans Frontières. Confl Health. 2010;4: 12. doi: 10.1186/1752-1505-4-12 20553624

25. STANFORD HIV DRUG RESISTANCE DATABASE Major HIV-1 Drug Resistance Mutations Major Non-Nucleoside RT Inhibitor (NNRTI) Resistance Mutations. 2017.

26. Khan S, Das M, Andries A, Deshpande A, Mansoor H, Saranchuk P, et al. Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India. Glob Heal …. 2014;1: 1–10. doi: 10.1136/amiajnl-2014-002841

27. Pujari SN, Makane A, Lodha A, Bele V, Joshi K. Short-term effectiveness and safety of third-line antiretroviral regimens among patients in Western India. J Acquir Immune Defic Syndr. 2014;65: e82–4. doi: 10.1097/QAI.0b013e3182a6104a 24442229

28. Saravanan S, Vidya M, Balakrishnan P, Kantor R, Solomon SS, Katzenstein D, et al. Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. Clin Infect Dis. 2012;54: 995–1000. doi: 10.1093/cid/cir967 22323567

29. Schoffelen AF, Wensing AMJ, Tempelman HA, Geelen SPM, Hoepelman AIM, Barth RE. Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa. doi: 10.1371/journal.pone.0058526

30. Wilhelmson S, Reepalu A, Tolera Balcha T, Jarso G, Björkman P. Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic. Glob Health Action. Taylor & Francis; 2016;9: 29943. doi: 10.3402/gha.v9.29943 26765104

31. Fox MP, Berhanu R, Steegen K, Firnhaber C, Ive P, Spencer D, et al. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Heal. 2016;21: 1131–1137. doi: 10.1111/tmi.12741 27383454

32. Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, et al. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS One. Public Library of Science; 2017;12: e0178942. doi: 10.1371/journal.pone.0178942 28582463

33. Gupta A, Saple DG, Nadkarni G, Shah B, Vaidya S, Hingankar N, et al. One-, Two-, and Three-Class Resistance among HIV-Infected Patients on Antiretroviral Therapy in Private Care Clinics: Mumbai, India. AIDS Res Hum Retroviruses. 2010; doi: 10.1089/aid.2009.0102 20063995

34. Sinha S, Shekhar RC, Ahmad H, Kumar N, Samantaray JC, Sreenivas V, et al. Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy. Curr HIV Res. 2012;10: 532–8. doi: 10.2174/157016212802429785 22716105

35. Blanco J-L, Varghese V, Rhee S-Y, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. Oxford University Press; 2011;203: 1204–14. doi: 10.1093/infdis/jir025 21459813